SANGAMO THERAPEUTICS, INC - Common Stock (SGMO)

Historical Holders from Q1 2014 to Q3 2025

Symbol
SGMO on Nasdaq
CUSIP
800677106
Type / Class
Equity / Common Stock
Shares outstanding
295M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
62.6M
Holdings value
$42.1M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
111
Number of buys
59
Number of sells
-34
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WASATCH ADVISORS LP 2.1% -62% $4.17M -$3.66M 6.19M -46.8% Wasatch Advisors LP Sep 30, 2025

Institutional Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 62.6M $42.1M -$4.09M $0.67 111
2025 Q2 73.2M $39.6M -$1.37M $0.54 110
2025 Q1 52.6M $34.5M -$6.97M $0.66 118
2024 Q4 61.5M $62.8M +$5.84M $1.02 125
2024 Q3 55.9M $48.4M -$13.2M $0.87 101
2024 Q2 86.9M $31.1M -$5.53M $0.36 126
2024 Q1 100M $67.2M +$9.59M $0.67 126
2023 Q4 86.9M $47.2M -$9.27M $0.54 128
2023 Q3 102M $61.3M -$4.25M $0.60 130
2023 Q2 106M $137M -$10.8M $1.30 148
2023 Q1 112M $197M +$12M $1.76 178
2022 Q4 104M $326M +$18.1M $3.14 178
2022 Q3 97.3M $477M +$38.5M $4.90 188
2022 Q2 89.6M $371M +$44.1M $4.14 174
2022 Q1 79.9M $465M +$13.3M $5.81 184
2021 Q4 76.8M $577M +$14.7M $7.50 181
2021 Q3 75.2M $679M -$11.3M $9.01 184
2021 Q2 76.1M $911M -$39.6M $11.97 191
2021 Q1 79.3M $993M +$8.74M $12.53 190
2020 Q4 78.2M $1.22B -$2.92M $15.61 219
2020 Q3 81.6M $772M +$39.7M $9.45 202
2020 Q2 77M $690M +$38.3M $8.96 197
2020 Q1 74M $471M -$44.2M $6.37 173
2019 Q4 78.4M $656M -$35.5M $8.37 187
2019 Q3 82.1M $744M +$18.2M $9.05 178
2019 Q2 79.8M $860M +$188M $10.77 180
2019 Q1 65.9M $628M +$8.49M $9.54 177
2018 Q4 63.9M $734M -$24.5M $11.48 187
2018 Q3 64.6M $1.1B +$6.26M $16.95 216
2018 Q2 64.7M $919M +$102M $14.20 209
2018 Q1 57.2M $1.09B +$32.1M $19.00 207
2017 Q4 55.6M $911M +$36.6M $16.40 168
2017 Q3 54.7M $820M +$37.4M $15.00 150
2017 Q2 53M $467M +$101M $8.80 147
2017 Q1 41.9M $218M +$36.4M $5.20 116
2016 Q4 41.3M $126M -$12M $3.05 120
2016 Q3 44M $203M -$12.2M $4.63 121
2016 Q2 46.2M $268M -$15.6M $5.79 136
2016 Q1 48.7M $292M -$4.35M $6.05 142
2015 Q4 49.1M $448M -$26.3M $9.13 139
2015 Q3 52.7M $297M -$28.7M $5.64 143
2015 Q2 50.5M $560M -$37.9M $11.09 157
2015 Q1 52.3M $819M +$52.3M $15.68 168
2014 Q4 47.6M $724M -$12.2M $15.21 159
2014 Q3 48.5M $523M -$10.7M $10.79 158
2014 Q2 48.9M $746M -$18.4M $15.27 155
2014 Q1 48.3M $872M +$52.9M $18.08 150